Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Blood (2024) 144 (19): 2063–2066.

https://doi.org/10.1182/blood.2024025681

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study

Blood (2023) 142 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2023-179303

Published: 2023

Journal Articles

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

Blood (2023) 142 (Supplement 1): 67.

https://doi.org/10.1182/blood-2023-190316

Published: 2023

Journal Articles

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Matthew J. Maurer, Arushi Khurana, Umar Farooq, Jason T. Romancik, Jonathan W. Friedberg, Izidore S. Lossos, Brad S. Kahl, Peter Martin, Dai Chihara, Andrew L. Feldman, Sergei Syrbu, David L Jaye, Elliot Cahn, Thomas M. Habermann, Brian K. Link, James R. Cerhan, Christopher R. Flowers, Loretta J. Nastoupil, Grzegorz S. Nowakowski

Blood (2023) 142 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2023-187350

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Sanjal H Desai, Raphael Mwangi, Yucai Wang, Umar Farooq, Eric Mou, Andrew L. Feldman, Sergei Syrbu, Susan L. Slager, Grzegorz S. Nowakowski, Matthew J. Maurer, Neil E. Kay, Thomas M. Habermann, Brian K. Link, Carrie A. Thompson, James R. Cerhan

Blood (2022) 140 (Supplement 1): 1934–1936.

https://doi.org/10.1182/blood-2022-165207

Published: 2022

Journal Articles

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

Yucai Wang, Melissa C. Larson, Alessia Castellino, Matthew J. Maurer, Andrew L. Feldman, Sergei Syrbu, Brian K. Link, Umar Farooq, David J. Inwards, Jonas Paludo, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan, Grzegorz S. Nowakowski

Blood (2021) 138 (Supplement 1): 2429.

https://doi.org/10.1182/blood-2021-147538

Published: 2021

Journal Articles

High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-134941

Published: 2020

Journal Articles

Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis

Carla Casulo, MD, Myla Strawderman, MS, Raphael Steiner, MD, Carolyne Delage, MD, Tina Faugh, Matthew J. Maurer, MS, Brian K. Link, MD, Allison C. Rosenthal, D.O., Colleen Ramsower, B.S. M.B., Richard Burack, MD PhD, Sergei Syrbu, MD PhD, Andrew L. Feldman, MD, Philip J Rock, James R. Cerhan, MD PhD, Christopher Flowers, MDMS, Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD MSSc

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-143171

Published: 2020

Journal Articles

Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era

Aung M Tun, MD, Raphael Mwangi, Brian K. Link, MD, Andrew L. Feldman, MD, Matthew J. Maurer, MS, Thomas E. Witzig, MD, Carrie A. Thompson, MD, Anne J. Novak, PhD, Jose C Villasboas, MD, Umar Farooq, MD, Sergei Syrbu, MD PhD, James R. Cerhan, MD PhD, Thomas M. Habermann, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139814

Published: 2020

Journal Articles

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Patrizia Mondello, MD PhD MSc, Angelo Fama, MD, Melissa C Larson, Zhi-Zhang Yang, MD, Jose C Villasboas, Andrew L. Feldman, MD, Susan L Slager, PhD, Brian K. Link, MD, Sergei Syrbu, MD PhD, Anne J Novak, PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz Nowakowski, MD, James R. Cerhan, MD PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 121.

https://doi.org/10.1182/blood-2019-126233

Published: 2019

Journal Articles

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Seth M Maliske, MD, Matthew J. Maurer, MS, Carrie A. Thompson, MD, Luis Porrata, MD, Ivana Micallef, MD, Rebecca L. King, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Margarida Magalhaes Silverman, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, David James J Inwards, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Patrick Johnston, MD PhD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 2896.

https://doi.org/10.1182/blood-2019-124579

Published: 2019

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Namrata Singh, MD, Sarah L Mott, Ashley Noel McCarthy, MPH, Sergei Syrbu, MD PhD, Thomas M. Habermann, MD, Andrew L. Feldman, MD, Susan L Slager, PhD, Grzegorz Nowakowski, MD, Thomas E. Witzig, MD, Umar Farooq, MD, James R. Cerhan, MD PhD, Zuhair Ballas, Brian K. Link, MD

Blood (2019) 134 (Supplement_1): 1604.

https://doi.org/10.1182/blood-2019-122737

Published: 2019

Journal Articles

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Blood (2019) 134 (Supplement_1): 1610.

https://doi.org/10.1182/blood-2019-126068

Published: 2019

Journal Articles

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Matthew J. Maurer, MS, Umar Farooq, MD, Madison M Wahlen, Thomas M. Habermann, MD, Gita Thanarajasingam, MD, Sergei Syrbu, MD PhD, William R. Macon, MD, Patrick Johnston, MD, Ivana Micallef, MD, Luis Porrata, MD, Susan L. Slager, PhD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Brian K. Link, MD

Blood (2018) 132 (Supplement 1): 4204.

https://doi.org/10.1182/blood-2018-99-114331

Published: 2018

Journal Articles

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

Alessia Castellino, MD, Melissa C. Larson, MS, Matthew J. Maurer, MS, Susan L. Slager, PhD, Cristine Allmer, BS, Jonathon B. Cohen, MD MS, Andrew L. Feldman, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Umar Farooq, MD, David J Inwards, MD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD

Blood (2018) 132 (Supplement 1): 4140.

https://doi.org/10.1182/blood-2018-99-119595

Published: 2018

Journal Articles

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States

Blood (2018) 132 (Supplement 1): 1702.

https://doi.org/10.1182/blood-2018-99-114281

Published: 2018

Journal Articles

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Blood (2017) 130 (Supplement 1): 4115.

https://doi.org/10.1182/blood.V130.Suppl_1.4115.4115

Published: 2017

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Blood (2017) 130 (Supplement 1): 2633.

https://doi.org/10.1182/blood.V130.Suppl_1.2633.2633

Published: 2017

Journal Articles

Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials

Matthew J Maurer, MS, Brian K Link, MD, Thomas M. Habermann, MD, Carrie A. Thompson, MD, Cristine Allmer, BS, Patrick B. Johnston, MD PhD, Ivana Micallef, MD, David J. Inwards, MD, Umar Farooq, MD, William R. Macon, MD, Sergei Syrbu, MD, Andrew L Feldman, MD, Susan L. Slager, PhD, George J. Weiner, MD, Stephen Ansell, MD PhD, James R Cerhan, MD PhD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD

Blood (2016) 128 (22): 3034.

https://doi.org/10.1182/blood.V128.22.3034.3034

Published: 2016

NARROW

Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis

Real-World Impact of Differences in the World Health Organization (WHO) Classification and International Consensus Classification (ICC) Systems on the Diagnosis of Non-Hodgkin Lymphoma: An Analysis from the LEO Cohort Study

Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL- BCL6 ) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications

The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell Lymphoma

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era

Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era

High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles

Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis

Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era

Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States

Diagnosis-to-Treatment Interval (DTI) Remains Associated with Adverse Clinical Characteristics and Outcome in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma Treated on Clinical Trials

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only